Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart

Toxicology Letters

Volumn 161, Issue 1, 2006, Pages 37-42

  Plandé, Joëlle ^a,b   Platel, Denis ^a,b   Tariosse, Liliane ^c   Robert, Jacques ^a,b  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

Author keywords

Anthracyclines; Cardiac toxicity models; Dexrazoxane

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; RAZOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; HEART PERFUSION; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TIME SERIES ANALYSIS;

ANIMALIA;

EID: 28844456361     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2005.07.013     Document Type: Article

References (15)

1. R.S. Cvetkovic, and L.J. Scott Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy Drugs 65 2005 1005 1024
2. B.B. Hasinoff, K. Hellmann, E.H. Herman, and V.J. Ferrans Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines Curr. Med. Chem. 5 1998 1 28
3. E.H. Herman, J. Zhang, S.E. Lipshultz, N. Rifai, D. Chadwick, K. Takeda, Z.X. Yu, and V.J. Ferrans Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin J. Clin. Oncol. 17 1999 2237 2243
4. K.F. Hofland, A.V. Thougaard, M. Sehested, and P.B. Jensen Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin Clin. Cancer Res. 11 2005 3915 3924
5. A.R. Imondi, P. Della Torre, G. Mazue, T.M. Sullivan, T.L. Robbins, L.M. Hagerman, A. Podesta, and G. Pinciroli Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs Cancer Res. 56 1996 4200 4204
6. R. Ishida, T. Miki, T. Narita, R. Yui, M. Sato, K.R. Utsumi, K. Tanabe, and T. Andoh Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors Cancer Res. 51 1991 4909 4916
7. B.H. Lorell, L.F. Wexler, S. Momomura, E. Weinberg, and C.S. Apstein The influence of pressure overload left ventricular hypertrophy on diastolic properties during hypoxia in isovolumically contracting rat hearts Circ. Res. 58 1986 653 663
8. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol. Rev. 56 2004 185 229
9. D. Platel, S. Bonoron-Adèle, R.K. Dix, and J. Robert Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin Br. J. Cancer 81 1999 24 27
10. D. Platel, P. Pouna, S. Bonoron-Adèle, and J. Robert Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model Anticancer Drugs 10 1999 671 676
11. D. Platel, P. Pouna, S. Bonoron-Adèle, and J. Robert Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart Toxicol. Appl. Pharmacol. 163 2000 135 140
12. P. Pouna, S. Bonoron-Adèle, G. Gouverneur, L. Tariosse, P. Besse, and J. Robert Development of the model of rat isolated perfused heart for the evaluation of anthracyline cardiotoxicity and its circumvention Br. J. Pharmacol. 117 1996 1593 1599
13. K. Shan, A.M. Lincoff, and J.B. Young Anthracycline-induced cardiotoxicity Ann. Intern. Med. 125 1996 47 58
14. S.M. Swain, F.S. Whaley, M.C. Gerber, S. Weisberg, M. York, D. Spicer, S.E. Jones, S. Wadler, A. Desai, C. Vogel, J. Speyer, A. Mittelman, S. Reddy, K. Pendergrass, E. Velez-Garcia, M.S. Ewer, J.R. Bianchine, and R.A. Gams Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J. Clin. Oncol. 15 1997 1318 1332
15. L.R. Wiseman, and C.M. Spencer Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy Drugs 56 1998 385 403